B
Benoit Viollet
Researcher at University of Paris
Publications - 379
Citations - 45591
Benoit Viollet is an academic researcher from University of Paris. The author has contributed to research in topics: AMPK & AMP-activated protein kinase. The author has an hindex of 95, co-authored 358 publications receiving 39666 citations. Previous affiliations of Benoit Viollet include Pasteur Institute & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
TL;DR: A molecular mechanism for regulation of the mammalian autophagy-initiating kinase Ulk1, a homologue of yeast ATG1, is demonstrated and a signalling mechanism for UlK1 regulation and autophagic induction in response to nutrient signalling is revealed.
Journal ArticleDOI
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Daniel F. Egan,David B. Shackelford,Maria M. Mihaylova,Sara Gelino,Rebecca A. Kohnz,William B. Mair,Debbie S. Vasquez,Aashish Joshi,Dana M. Gwinn,Rebecca C. Taylor,John M. Asara,James A. J. Fitzpatrick,Andrew Dillin,Benoit Viollet,Mondira Kundu,Malene Hansen,Reuben J. Shaw +16 more
TL;DR: Reconstitution of ULK1-deficient cells with a mutant ULK2 that cannot be phosphorylated by AMPK revealed that such phosphorylation is required for mitochondrial homeostasis and cell survival during starvation.
Journal ArticleDOI
Cellular and molecular mechanisms of metformin: an overview
Benoit Viollet,Benoit Viollet,Benoit Viollet,Bruno Guigas,Nieves Sanz Garcia,Nieves Sanz Garcia,Nieves Sanz Garcia,Jocelyne Leclerc,Jocelyne Leclerc,Jocelyne Leclerc,Marc Foretz,Marc Foretz,Marc Foretz,Fabrizio Andreelli +13 more
TL;DR: Emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.
Journal ArticleDOI
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
Marc Foretz,Sophie Hébrard,Jocelyne Leclerc,Elham Zarrinpashneh,Maud Soty,Gilles Mithieux,Kei Sakamoto,Fabrizio Andreelli,Benoit Viollet +8 more
TL;DR: It is found that in mice lacking AMPK in the liver, blood glucose levels were comparable to those in wild-type mice, and the hypoglycemic effect of metformin was maintained, demonstrating that met formin inhibits hepatic gluconeogenesis in an LKB1- and AMPK-independent manner via a decrease in hepatic energy state.
Journal ArticleDOI
Metformin: From Mechanisms of Action to Therapies
Marc Foretz,Bruno Guigas,Luc Bertrand,Michael Pollak,Benoit Viollet,Benoit Viollet,Benoit Viollet +6 more
TL;DR: Convincing data place energy metabolism at the center of metformin's mechanism of action in diabetes and may also be of importance in cardiovascular diseases and cancer.